James E. Hoffman
A5102914339- Multiple Myeloma Research and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Parathyroid Disorders and Treatments
- Lymphoma Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Immunotherapy and Immune Responses
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Pneumocystis jirovecii pneumonia detection and treatment
- Glycosylation and Glycoproteins Research
- Neuroendocrine Tumor Research Advances
- SARS-CoV-2 and COVID-19 Research
- IgG4-Related and Inflammatory Diseases
- Immunodeficiency and Autoimmune Disorders
- CNS Lymphoma Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- COVID-19 Clinical Research Studies
- Synthesis and Biological Evaluation
University of Miami
2015-2024
Sylvester Comprehensive Cancer Center
2015-2024
University of Miami Health System
2019-2024
University of Miami Hospital
2023
St. Jude Children's Research Hospital
2021-2022
University of Fort Lauderdale
2017-2019
Tisch Hospital
2018
NYU Langone Health
2018
Mayo Clinic in Florida
2018
Icahn School of Medicine at Mount Sinai
2018
Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces accumulation activation tumor suppressor proteins, inhibits factor κB, reduces oncoprotein messenger RNA translation, is potential novel treatment for myeloma refractory to current therapeutic options.We administered oral selinexor (80 mg) plus dexamethasone (20 twice weekly patients with who had previous exposure bortezomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, an alkylating...
8006 Background: Linvoseltamab is a BCMA×CD3 bispecific antibody with encouraging efficacy and manageable safety profile in patients (pts) relapsed/refractory multiple myeloma (RRMM) (Bumma et al. ASH 2022). Two Phase (Ph) 2 full dose cohorts (50 mg 200 mg) the LINKER-MM1 (NCT03761108) trial were studied to optimize selection. Methods: Ph enrolled adults MM who progressed on/after ≥3 lines of therapy (LoT) including proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 (Ab),...
PURPOSE We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg 200 doses linvoseltamab, B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM). METHODS Phase II eligible patients had RRMM that either progressed on/after ≥three lines therapy including proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 or was triple-class (PI/IMiD/anti-CD38) refractory. treatment once week through 14 then every 2...
Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition translation oncoprotein mRNAs. We studied selinexor combination low-dose dexamethasone patients multiple myeloma refractory to most active available agents. Patients Methods This phase II trial evaluated 80 mg 20 mg, both orally twice weekly, bortezomib, carfilzomib,...
The treatment of systemic light-chain (AL) amyloidosis with symptomatic cardiac involvement at diagnosis remains a challenge. We report the results 40 consecutive newly diagnosed AL patients who were not candidates for stem cell transplant and therefore received monthly oral melphalan dexamethasone. Median survival was 10.5 months baseline predictors included gender, troponin I interventricular septal thickness. most significant predictor response to therapy. haematological rate 58% (23/40)...
Glucagon response to insulin hypoglycemia was tested in diabetics with autonomic neuropathy (N=9), without (N=8), and normals (N=9). With similar levels of hypoglycemia, growth hormone plasma cortisol increased all groups. The glucagon (121 ± 19 vs. 308 30 pg./ml., mean S. E. M. baseline peak) significantly less nonneuropathic than (128 13 209 30) absent neuropathic 23 115 20). Arginine stimulation produced a the (106 16 523 103). data indicate that capacity release during is lost diabetic...
Abstract Background We report pivotal results from the registrational filing data cut-off (DCO) of 200 mg dose used in LINKER-MM1 (NCT03761108) clinical trial, testing safety and efficacy linvoseltamab (a B-cell maturation antigen × CD3 antibody [Ab]) as treatment for relapsed/refractory multiple myeloma (RRMM). Methods Eligible patients had RRMM that either progressed on/after ≥3 lines therapy included a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 Ab or was...
Patients with multiple myeloma-bearing translocation t(11;14) have recently been shown to benefit from the apoptosis-inducing drug venetoclax; however, lacks FDA approval in myeloma thus far due a potential safety signal overall patient population. Selinexor is an inhibitor of nuclear export that FDA-approved for patients refractory lines therapy. Here, we report four t(11;14), concomitant administration venetoclax and selinexor was safe associated disease response. Moreover, combination...
Background: Linvoseltamab is a BCMA×CD3 bispecific antibody with encouraging efficacy and manageable safety profile in patients (pts) relapsed/refractory multiple myeloma (RRMM) (Bumma et al. ASH 2022). Aims: Two Phase (Ph) 2 full dose cohorts (50 mg 200 mg) the LINKER-MM1 (NCT03761108) trial were studied to optimize selection. Methods: Ph enrolled adults MM who progressed on/after ≥3 lines of therapy (LoT) including proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 (Ab),...
The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy 90yttrium (90Y) ibritumomab tiuxetan as in MZL (NCT00453102). A total 16 were enrolled, 81% advanced-stage disease 44% bulky disease. overall response rate (ORR) at 12 weeks post-therapy was 87.5% (90% confidence interval [CI]: 65.6–97.7%), including a complete eight (50%), unconfirmed one (6%) partial five (31%) patients....